3
Participants
Start Date
November 21, 2019
Primary Completion Date
February 17, 2020
Study Completion Date
February 17, 2020
T-Guard
Patients will receive 4 doses of T-Guard treatment, administered intravenously as four 4-hour infusions at least two calendar days (no less than 40 hours) apart. Each dose consists of 4 mg/m\^2 Body Surface Area (BSA).
Mount Sinai Medical Center, New York
University of Pennsylvania, Philadelphia
Children's National Medical Center, Washington D.C.
University of Maryland, Baltimore
Johns Hopkins University, Baltimore
Emory University, Atlanta
H. Lee Moffitt Cancer Center, Tampa
Ohio State University, Columbus
Cincinnati Children's Hospital Medical Center, Cincinnati
Indiana University, Indianapolis
University of Michigan, Ann Arbor
Medical College of Wisconsin, Milwaukee
University of Wisconsin, Madison
University of Minnesota, Minneapolis
Mayo Clinic, Rochester
Washington University in St. Louis, St Louis
University of Kansas, Westwood
University of Nebraska, Omaha
Baylor College of Medicine, Houston
University of Utah, Salt Lake City
Children's Hospital Los Angeles, Los Angeles
City of Hope National Medical Center, Duarte
Oregon Health & Science University, Portland
Fred Hutchinson Cancer Research Center, Seattle
Lead Sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Blood and Marrow Transplant Clinical Trials Network
NETWORK
National Cancer Institute (NCI)
NIH
National Marrow Donor Program
OTHER
Xenikos
INDUSTRY